Healthcare

Abu Dhabi hypertension program to test AI-supported care workflows

A planned Abu Dhabi initiative will test AI for hypertension management, clinical-trial matching and evidence generation.

AstraZeneca and Oracle announced a global AI collaboration that includes an initial hypertension-focused project in Abu Dhabi. The program will work with M42, a healthcare company, to explore how AI can identify patients whose hypertension is not adequately controlled and help care teams apply recommended treatments. It will also assess whether eligible patients can be found earlier for clinical trials. The broader partnership is intended to address delayed diagnosis, lengthy referral pathways and the difficulty of connecting suitable patients with research studies. Planned use cases include clinical-trial matching, earlier diagnosis, drug-safety monitoring and use of real-world evidence across the medicine lifecycle. The companies expect further projects across the United States, Europe and the Middle East, working with governments and healthcare organizations. For the UAE, the Abu Dhabi pilot provides a concrete test of AI-supported population health and research workflows rather than a purely experimental technology demonstration. If effective, the approach could improve access to trials, support more timely intervention for uncontrolled hypertension and connect routine care data with evidence generation. The source describes the arrangement as a collaboration announced on 20 October 2026 and does not report measured outcomes yet.

Original source: EMEA Outlook

Related RAQI solutions

In-depth analysis on RAQI Insight

Work with RAQI